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Abstract
Background: Cerebral microbleeds can confer a high risk of intracerebral hemorrhage, ischemic stroke, death and
dementia, but estimated risks remain imprecise and often conflicting. We investigated the association between cerebral
microbleeds presence and these outcomes in a large meta-analysis of all published cohorts including: ischemic stroke/
TIA, memory clinic, ‘‘high risk’’ elderly populations, and healthy individuals in population-based studies.
Methods: Cohorts (with> 100 participants) that assessed cerebral microbleeds presence on MRI, with subsequent
follow-up (3 months) were identified. The association between cerebral microbleeds and each of the outcomes
(ischemic stroke, intracerebral hemorrhage, death, and dementia) was quantified using random effects models of (a)
unadjusted crude odds ratios and (b) covariate-adjusted hazard rations.
Results: We identified 31 cohorts (n¼ 20,368): 19 ischemic stroke/TIA (n¼ 7672), 4 memory clinic (n¼ 1957), 3 high
risk elderly (n¼ 1458) and 5 population-based cohorts (n¼ 11,722). Cerebral microbleeds were associated with an
increased risk of ischemic stroke (OR: 2.14; 95% CI: 1.58–2.89 and adj-HR: 2.09; 95% CI: 1.71–2.57), but the relative
increase in future intracerebral hemorrhage risk was greater (OR: 4.65; 95% CI: 2.68–8.08 and adj-HR: 3.93; 95% CI:
2.71–5.69). Cerebral microbleeds were an independent predictor of all-cause mortality (adj-HR: 1.36; 95% CI: 1.24–
1.48). In three population-based studies, cerebral microbleeds were independently associated with incident dementia
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(adj-HR: 1.35; 95% CI: 1.00–1.82). Results were overall consistent in analyses stratified by different populations, but with
different degrees of heterogeneity.
Conclusions: Our meta-analysis shows that cerebral microbleeds predict an increased risk of stroke, death, and
dementia and provides up-to-date effect sizes across different clinical settings. These pooled estimates can inform clinical
decisions and trials, further supporting cerebral microbleeds role as biomarkers of underlying subclinical brain pathology
in research and clinical settings.
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magnetic resonance imaging
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Introduction
Cerebral microbleeds (CMBs) are small round hypoin-
tense lesions detected on paramagnetic-sensitive MRI
sequences, including T2*-weighted gradient-recalled
echo (T2*-GRE) and susceptibility-weighted imaging
(SWI).1 Although the mechanisms leading to CMBs
remain elusive, results from limited histopathological
correlation studies, suggest that most MR-visible lesions
correspond to focal deposits of blood-breakdown prod-
ucts in perivascular tissue,2,3 likely representing blood
leakage from microvasculopathies. CMBs have received
enormous attention in the literature—the broad consen-
sus is that they constitute biomarkers of ‘‘silent’’ or
‘‘subclinical’’ small vessel disease in the brain.1,4
In this context, much of the enduring interest in the
topic relates to the implicit clinical conundrums cre-
ated by the high prevalence of CMBs in many diﬀer-
ent populations.5,6 CMBs are found in up to 5–21%
of the general population, 30–40% of patients with
ischemic stroke, 60–68% of patients with primary
ICH, and 15–25% of memory clinic patients, includ-
ing Alzheimer’s disease and vascular cognitive impair-
ment.1 In these settings, CMBs generate increasingly
common clinical dilemmas due to concern that they
may be a marker of future stroke (both ischemic
stroke and intracerebral hemorrhage ICH) raising
questions regarding optimal antithrombotic ther-
apy.7,8 Available data also suggest that CMBs can
contribute to dementia,9,10 and increase overall
mortality.11,12
Several single-center cohorts have assessed the rela-
tion between CMBs and risk of stroke, dementia, and
death, with partly conﬂicting results and wide conﬁ-
dence intervals (CIs). Accurate estimates of these risks
are needed to inform clinical decisions, and potentially
allow the incorporation of CMBs as an informative
biomarker in clinical trials.13 So far, previous meta-
analyses have only focused on patients with a history
of ischemic stroke or TIA (but not other settings),7,14
and demonstrated that CMBs presence increases the
risk of recurrent stroke (OR: 2.25; 95% CI: 1.70–2.98;
p< 0.0001), either hemorrhagic or ischemic.7
Therefore, given new data in the ﬁeld (through the
International META-MICROBLEEDS Initiative15),
we systematically reviewed and synthesized in meta-
analyses all published longitudinal observational
studies testing the association between CMBs with
risk of ICH, ischemic stroke, dementia, and death, in
the general population, high-risk populations, and
in hospital-based settings (stroke/TIA and memory
clinics). In addition, in the meta-anaysis syntheses for
each outcome in relation to CMBs presence, we provide
both unadjusted and adjusted estimates–a unique fea-
ture in the literature on this topic, which has not been
attempted in the past.
Methods
The study was conducted with reference to the
PRISMA,16 the MOOSE17 guidelines, and the Cochrane
Handbook for Systematic Reviews of Interventions.
A pre-speciﬁed summary protocol was developed in-house
in January 2016 (not published or registered).
Search strategy and study selection
We searched PubMed for potentially eligible studies
between 1 January 1995 and 1 March 2016, using a
combination of search terms and Medical Subject
Headings (MeSH): ((microbleed*) OR (microhemor-
rhag*) OR (microhemorrhag*) OR (‘‘dot-like’’))
AND (MRI OR SWI OR T2* OR suscept* OR hemo-
sid*) AND ((brain OR cerebr* OR (cerebral small
vessel disease) OR (vascular dementia) OR
(Alzheimer disease) OR (Alzheimer’s disease) OR
cognit* OR dement*)). The systematic literature
search was updated on 10 February 2017. All identi-
ﬁed citations (comprising titles, abstracts and key-
words) were retrieved and imported into
ABSTRACKR,18 a collaborative web-based
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annotation tool which utilizes interactive machine
learning components for the citation screening task.
We also used snowballing to screen the reference lists
of all included articles, relevant review articles, meta-
analyses, and author’s own ﬁles (including regular
PubMed searches updates on the topic for the last
six years). To identify recent studies not yet published
as full papers, we searched abstract books from the
following recent conferences: European Stroke
Organization Conference 2014–2016 and
International Stroke Conference 2014–2016. The
abstracts of all papers identiﬁed from the initial
searches were reviewed by two authors, who also
then reviewed the full text of all eligible studies inde-
pendently. The ﬁnal list of included studies was
decided upon consensus.
Retrospective or prospective studies (published as
full papers or conference abstracts) were eligible for
inclusion regardless of language if they characterized
CMBs presence on MRI at baseline with subsequent
follow-up for the development of future symptomatic
stroke, death, or dementia. Other speciﬁc inclusion cri-
teria were: (1) studies of at least 100 adult subjects
(aged> 18 years); (2) MRI determination of CMBs at
baseline using standard criteria; (3) ascertainment of
the outcomes of interest after the baseline MRI
during follow-up; (4) quantiﬁcation of the risk for
each outcome in relation to the presence CMBs.
Studies including only patients with spontaneous ICH
were not included in this analysis because of the diﬀer-
ent clinical signiﬁcance of CMBs in this setting. For
studies with more than one publication describing
results among overlapping groups of participants and
with the same outcome measure, we included only the
dataset with the longest follow-up, or the dataset with
the largest number of participants if the follow-up
period was identical.
All papers from the same cohort reporting diﬀerent
primary outcomes of interest were included.
Outcome measures
The primary outcomes of interest were: (a) stroke,
deﬁned as an acute onset focal neurological deﬁcit of
presumed vascular cause lasting at least 24 h or inter-
rupted by death within 24 hours, and diagnosed as (i)
ischemic stroke or (ii) spontaneous intracerebral hem-
orrhage (presumed to be due to small vessel disease)
based on standardized brain imaging criteria; (b)
death of any cause; and (c) new onset dementia
measured by standard criteria in each study, such as
diagnostic and statistical manual of mental disorders
IV (DSM IV), international classiﬁcation of disease-
10 (ICD-10), CDR, or a mini-mental state examination
(MMSE) score of less than 24.
Data extraction and quality assessment
We classiﬁed studies as being in ischemic stroke/TIA
populations, memory clinic populations, ‘‘high risk’’
elderly populations (i.e. if carried out in people selected
for the presence of high risk factor proﬁle at baseline)
and asymptomatic individuals in a population-based
setting (‘‘general population’’). For each study, we
extracted information on study design, number, and
nature of participants (including mean age and sex),
characteristics of MRI sequences used for CMBs
rating, duration of follow-up, and number of partici-
pants with the outcomes of interest per CMBs presence
group. When available, adjusted estimates from multi-
variable models of the independent association between
CMBs and the outcomes were extracted as hazard
ratios. Two authors independently extracted data and
disagreements were resolved by consensus.
Studies were critically appraised against an 8-item
tool published by the Cochrane Methods Bias group.19
Data synthesis and statistical analysis
Data were pooled in a meta-analysis when at least two
studies with relevant data per outcome were available.
In all analyses, we used a random eﬀects model with
DerSimonian-Laird weights.20 First, in unadjusted
analyses, we quantiﬁed the strength of the association
between CMBs presence and each of the outcomes
(stroke—ischemic and hemorrhagic, death, and demen-
tia) using odds ratios (OR) and their corresponding
95% CIs, with the inverse variance method for weight-
ing. Second, in adjusted analyses, for each of the out-
comes, we pooled the covariate-adjusted HRs as
provided from relevant multivariable survival analysis
models in included studies, calculating pooled adjusted
hazard ratios using the random eﬀects inverse variance
method. Meta-analyses were performed both separately
by study setting/population, and overall. We assessed
statistical heterogeneity using I-squared statistics and
visually through inspection of the forest plot. Values
of 25%, 25% to 50%, and 50% were deﬁned as
low, moderate, and high degrees of heterogeneity, respect-
ively. We explored publication bias with funnel plots.
For the unadjusted analyses, we used meta-regression to
explore whether certain key baseline characteristics of the
included patient populations could have aﬀected our
results in a random-eﬀect univariable meta-regression
analyses. Meta-analyses were performed using Stata
13.0 (StataCorp LP, Texas).
Results
A total of 1251 titles and abstracts were screened, of
which 36 met the inclusion criteria and were pooled in
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meta-analyses (Figure 1). These reported data from 31
independent cohorts. Some cohorts reported diﬀerent
outcomes in separate papers, while some studies
contained data on more than one outcome in a
single publication. In summary, we included 20
studies of ischemic stroke/TIA patients (19 cohorts,
n¼ 7672),11,21–39 4 studies of memory clinic patients
(4 cohorts, n¼ 1957),40–43 4 studies in high-risk elderly
populations (3 cohorts, n¼ 1458)44–47 and 8 popula-
tion-based studies of healthy elderly participants
(5 cohorts, n¼ 11,722).12,48–54 Table 1 highlights key
baseline and methodological characteristics and out-
comes available in the included studies. No evidence
of publication bias was identiﬁed for any of the
outcomes and analyses (Egger’s test p> 0.3). Studies
published as conference abstracts (except for the
stroke outcomes in the Framingham Heart Study
and AGES Reykjavik Study) at the time of the ini-
tial literature search were then published as full
papers55–58 and identiﬁed in our ongoing real-time
search strategy as part of the META-MICROBLEEDS
Initiative.
CMBs and risk of ICH and ischemic stroke
Nineteen studies of ischemic stroke/TIA patients (n¼
7672),11,21–39 one memory clinic cohort (n¼ 333),40 and
ﬁve population-based studies (n¼ 13,864)48–50,52 exam-
ined the relation between CMBs presence and risk of
ICH and ischemic stroke.
In the pooled analyses of patients with ischemic
stroke/TIA, CMBs presence (vs. no CMBs) was asso-
ciated with an increased crude risk of ICH (OR: 3.71;
95% CI: 2.13–6.45, p< 0.0001) (Figure 2(a)) and recur-
rent ischemic stroke (OR: 1.84; 95% CI: 1.39–2.42,
p< 0.0001) (Figure 3(a)) during follow-up. Nine
cohorts (n¼ 4715) provided adjusted estimates for
CMBs and the risk of future stroke: ﬁve for symptom-
atic ICH (n¼ 2274)23,24,26,33,59 and seven for ischemic
stroke (n¼ 3257).23,24,29,31,33,36,38 In the pooled analysis
of these cohorts that provided adjusted estimates, CMBs
presence was independently associated with increased
risk of ICH (adj-HR: 3.10; 95% CI: 1.78–5.40,
p< 0.0001) (Figure 2(b)), but the increase in the risk
for future ischemic stroke was relatively lower (adj-
Figure 1. Flow chart of study identification and selection process.
International Journal of Stroke, 0(0)
4 International Journal of Stroke 0(0)
T
a
b
le
1
.
P
ar
ti
ci
p
an
t
ch
ar
ac
te
ri
st
ic
s
an
d
m
e
th
o
d
o
lo
gi
ca
l
as
p
e
ct
s
o
f
in
cl
u
d
e
d
st
u
d
ie
s
St
u
d
y
C
o
u
n
tr
y
(s
tu
d
y
p
e
ri
o
d
)
Se
tt
in
g/
co
h
o
rt
d
e
si
gn
C
as
e
s
n
u
m
b
e
r
(%
m
al
e
)
A
ge
(m
e
an
)
H
T
N
(%
)
D
M
(%
)
A
n
ti
p
la
t.
(%
)
A
n
ti
co
ag
s
(%
)
M
R
I
p
ar
am
e
te
rs
A
ve
ra
ge
FU
(m
o
)
P
e
rs
o
n
-
ye
ar
s
o
f
FU
O
u
tc
o
m
e
s
FU m
e
th
o
d
Se
q
u
e
n
ce
Fi
e
ld
st
re
n
gt
h
(T
e
sl
a)
E
ch
o
ti
m
e
(m
s)
Is
c
h
e
m
ic
st
ro
k
e
/T
IA
c
o
h
o
rt
s
Fa
n
e
t
al
.2
1
C
h
in
a
(1
9
9
9
–
2
0
0
0
)
P
ro
sp
e
ct
iv
e
1
2
1
(6
8
%
)
6
8
6
9
%
3
2
%
8
0
%
6
%
T
2
*-
G
R
E
1
.5
3
0
2
8
2
2
7
St
ro
ke
,
D
e
at
h
Te
le
p
h
o
n
e
In
p
e
rs
o
n
N
o
te
s
Im
ai
zu
m
i
e
t
al
.2
2
Ja
p
an
(1
9
9
9
–
2
0
0
3
)
P
ro
sp
e
ct
iv
e
1
3
8
(6
6
%
)
6
6
7
3
%
–
3
3
%
2
%
T
2
*-
G
R
E
1
.5
2
6
2
2
–
St
ro
ke
Te
le
p
h
o
n
e
N
o
te
s
B
o
u
la
n
ge
r
e
t
al
.2
3
C
an
ad
a
(2
0
0
2
–
2
0
0
4
)
P
ro
sp
e
ct
iv
e
2
3
6
(5
5
%
)
–
6
0
%
5
5
%
–
–
T
2
*-
G
R
E
3
2
0
/4
5
1
8
2
7
5
St
ro
ke
,
D
e
at
h
Te
le
p
h
o
n
e
In
p
e
rs
o
n
N
ak
a
e
t
al
.2
4
Ja
p
an
(2
0
0
2
–
2
0
0
4
)
P
ro
sp
e
ct
iv
e
1
8
3
(6
3
%
)
6
7
7
0
%
2
6
%
9
3
2
T
2
*-
G
R
E
1
2
6
1
8
–
St
ro
ke
In
p
e
rs
o
n
H
u
an
g
e
t
al
.2
5
C
h
in
a
(2
0
0
4
)
R
C
T
6
3
6
(6
8
%
)
6
0
6
7
6
8
1
0
0
%
0
%
T
2
*-
G
R
E
1
.5
N
A
1
4
7
4
0
St
ro
ke
In
p
e
rs
o
n
So
o
e
t
al
.2
6
C
h
in
a
(1
9
9
9
–
2
0
0
4
)
P
ro
sp
e
ct
iv
e
9
0
8
(5
8
%
)
6
8
6
8
%
3
2
%
9
3
%
3
%
T
2
*-
G
R
E
1
.5
3
0
2
6
.6
2
0
1
3
St
ro
ke
,
D
e
at
h
(s
tr
o
ke
)
In
p
e
rs
o
n
O
X
V
A
SC
2
7
,2
8
U
K
(2
0
0
0
–
2
0
0
8
)
P
ro
sp
e
ct
iv
e
2
9
1
(5
1
%
)
6
6
6
3
%
–
3
3
%
4
%
T
2
*-
G
R
E
1
.5
9
5
/1
4
3
5
–
St
ro
ke
In
p
e
rs
o
n
T
h
ijs
e
t
al
.2
9
B
e
lg
iu
m
(2
0
0
3
–
2
0
0
5
)
P
ro
sp
e
ct
iv
e
4
8
7
(6
1
%
)
7
2
6
4
%
1
9
%
3
2
%
T
2
*-
G
R
E
1
.5
/3
3
5
/2
6
/1
6
2
6
1
0
7
1
St
ro
ke
In
p
e
rs
o
n
Te
le
p
h
o
n
e
N
o
te
s
So
n
g
e
t
al
.3
0
So
u
th
K
o
re
a
(2
0
0
5
–
2
0
1
2
)
R
e
tr
o
sp
e
ct
iv
e
(A
F)
5
5
0
(5
9
%
)
7
1
7
7
%
2
5
%
4
6
%
9
6
%
T
2
*-
G
R
E
3
1
6
3
7
–
St
ro
ke
D
e
at
h
(s
tr
o
ke
)
Te
le
p
h
o
n
e
N
o
te
s
C
o
d
in
g
d
at
a
Fl
u
ri
e
t
al
.3
1
Sw
it
ze
rl
an
d
(2
0
0
6
–
2
0
0
8
)
P
ro
sp
e
ct
iv
e
(T
IA
)
1
7
6
(6
1
%
)
7
1
7
2
%
1
8
5
7
7
%
1
2
%
T
2
*-
G
R
E
1
.5
1
5
3
–
St
ro
ke
In
p
e
rs
o
n
Im
ai
zu
m
i
e
t
al
.3
2
Ja
p
an
(2
0
0
4
–
2
0
1
0
)
P
ro
sp
e
ct
iv
e
5
6
2
7
1
6
4
%
–
7
5
%
1
8
%
T
2
*-
G
R
E
1
.5
2
6
3
1
–
St
ro
ke
Te
le
p
h
o
n
e
N
o
te
s
So
n
g
e
t
al
.1
1
So
u
th
K
o
re
a
(2
0
0
4
–
2
0
1
0
)
R
e
tr
o
sp
e
ct
iv
e
(A
F)
5
0
4
(5
7
%
)
7
0
7
8
%
2
5
%
-
9
7
%
T
2
*-
G
R
E
3
1
6
3
0
1
2
6
0
D
e
at
h
C
o
d
in
g
d
at
a
K
w
a
e
t
al
.3
3
N
e
th
e
rl
an
d
s
(2
0
0
0
–
2
0
1
0
)
P
ro
sp
e
ct
iv
e
3
9
7
(5
9
%
)
6
8
2
7
%
1
4
%
2
5
%
1
0
%
T
2
*-
G
R
E
1
.5
2
7
.6
4
6
1
5
0
9
St
ro
ke
,
D
e
at
h
Te
le
p
h
o
n
e
N
o
te
s (c
o
n
ti
n
u
e
d
)
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
St
u
d
y
C
o
u
n
tr
y
(s
tu
d
y
p
e
ri
o
d
)
Se
tt
in
g/
co
h
o
rt
d
e
si
gn
C
as
e
s
n
u
m
b
e
r
(%
m
al
e
)
A
ge
(m
e
an
)
H
T
N
(%
)
D
M
(%
)
A
n
ti
p
la
t.
(%
)
A
n
ti
co
ag
s
(%
)
M
R
I
p
ar
am
e
te
rs
A
ve
ra
ge
FU
(m
o
)
P
e
rs
o
n
-
ye
ar
s
o
f
FU
O
u
tc
o
m
e
s
FU m
e
th
o
d
Se
q
u
e
n
ce
Fi
e
ld
st
re
n
gt
h
(T
e
sl
a)
E
ch
o
ti
m
e
(m
s)
O
rk
e
n
e
t
al
.3
4
Tu
rk
e
y
(2
0
0
9
–
2
0
1
3
)
R
e
tr
o
sp
e
ct
iv
e
(A
F)
2
0
4
(5
7
%
)
6
9
8
8
%
2
5
%
2
7
%
1
0
0
%
T
2
*-
G
R
E
1
.5
1
5
2
4
–
St
ro
ke
In
p
e
rs
o
n
N
o
te
s
H
o
rs
tm
an
n
e
t
al
.3
5
G
e
rm
an
y
(2
0
0
9
–
2
1
2
)
P
ro
sp
e
ct
iv
e
2
6
5
(6
7
%
)
6
5
8
0
%
–
7
8
%
2
0
%
SW
I
3
1
9
.7
1
2
2
6
5
St
ro
ke
In
p
e
rs
o
n
N
o
te
s
Sh
o
am
an
e
sh
e
t
al
.3
6
,5
5
M
u
lt
ic
e
n
te
r
R
C
T
(S
P
S3
)
(L
ac
u
n
ar
)
1
2
7
8
(6
5
%
)
6
3
7
5
%
3
6
%
1
0
0
%
0
%
T
2
*-
G
R
E
1
.5
/3
–
4
0
–
St
ro
ke
,
D
e
at
h
In
p
e
rs
o
n
N
o
te
s
H
aj
i
e
t
al
.3
7
U
SA
(2
0
0
8
–
2
0
1
4
)
P
ro
sp
e
ct
iv
e
1
1
7
8
0
8
7
%
–
6
7
%
7
4
%
T
2
*-
G
R
E
1
.5
2
0
/1
5
/2
4
2
8
.8
3
2
2
St
ro
ke
,
D
e
at
h
In
p
e
rs
o
n
W
ri
tt
e
n
su
rv
ey
N
o
te
s
L
im
e
t
al
.3
8
So
u
th
K
o
re
a
(2
0
1
0
–
2
0
1
2
)
P
ro
sp
e
ct
iv
e
(T
IA
)
5
0
0
(5
8
%
)
6
5
6
7
%
3
0
%
9
1
%
1
5
%
T
2
*-
G
R
E
–
1
5
–
2
5
3
1
2
3
St
ro
ke
(e
ar
ly
)
In
p
e
rs
o
n
Te
le
p
h
o
n
e
C
h
ar
id
im
o
u
e
t
al
.3
9
Ja
p
an
(2
0
0
8
–
2
0
1
2
)
P
ro
sp
e
ct
iv
e
(A
F)
1
1
9
(5
4
%
)
7
6
7
1
%
2
8
%
4
2
%
8
6
%
T
2
*-
G
R
E
1
.5
2
6
1
7
–
St
ro
ke
In
p
e
rs
o
n
Te
le
p
h
o
n
e
N
o
te
s
H
ig
h
-r
is
k
e
ld
e
rl
y
c
o
h
o
rt
s
A
lt
m
an
n
-S
ch
n
e
id
e
r
e
t
al
.4
4
N
e
th
e
rl
an
d
s
P
ro
sp
e
ct
iv
e
(P
R
O
SP
E
R
)
4
3
4
(5
6
%
)
7
5
6
4
%
1
5
%
–
–
T
2
*-
G
R
E
1
.5
4
8
8
4
–
D
e
at
h
C
o
d
in
g
d
at
a
va
n
d
e
r
H
o
ls
t
e
t
al
.4
5
N
e
th
e
rl
an
d
s
(2
0
0
6
–
2
0
1
4
)
P
ro
sp
e
ct
iv
e
(R
U
N
D
M
C
)
5
0
3
(5
7
%
)
6
6
7
3
%
1
3
%
–
–
T
2
*-
G
R
E
1
.5
2
6
9
4
3
9
2
3
D
e
at
h
C
o
d
in
g
d
at
a
N
o
te
s
M
iw
a
e
t
al
.4
6
Ja
p
an
(2
0
0
1
–
2
0
0
9
)
P
ro
sp
e
ct
iv
e
(O
SA
C
A
2
)
5
2
4
(5
8
%
)
6
8
8
3
%
2
3
%
–
–
T
2
*-
G
R
E
1
.5
2
0
9
0
3
9
3
0
D
e
m
e
n
ti
a
In
p
e
rs
o
n
(M
M
SE
<
2
4
,
3
d
e
cl
in
e
,
o
r
C
D
R

1
,
D
SM
-I
II
-R
)
va
n
U
d
e
n
e
t
al
.4
7
N
e
th
e
rl
an
d
s
(2
0
0
6
–
2
0
1
2
)
P
ro
sp
e
ct
iv
e
(R
U
N
D
M
C
)
5
0
0
(5
7
%
)
6
6
–
–
–
–
T
2
*-
G
R
E
1
.5
2
0
6
2
.4
–
D
e
m
e
n
ti
a
In
p
e
rs
o
n
N
o
te
s
(M
M
SE
<
2
6
,
3
d
e
cl
in
e
,
o
r
M
IN
I)
M
e
m
o
r
y
c
li
n
ic
c
o
h
o
rt
s
B
e
n
e
d
ic
tu
s
e
t
al
.4
0
N
e
th
e
rl
an
d
s
(2
0
0
2
–
2
0
0
9
)
3
3
3
(5
8
%
)
7
1
2
3
%
6
%
3
7
%
T
2
*-
G
R
E
1
/1
.5
/3
–
3
6
–
St
ro
ke
D
e
at
h
(c
o
n
ti
n
u
e
d
)
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
St
u
d
y
C
o
u
n
tr
y
(s
tu
d
y
p
e
ri
o
d
)
Se
tt
in
g/
co
h
o
rt
d
e
si
gn
C
as
e
s
n
u
m
b
e
r
(%
m
al
e
)
A
ge
(m
e
an
)
H
T
N
(%
)
D
M
(%
)
A
n
ti
p
la
t.
(%
)
A
n
ti
co
ag
s
(%
)
M
R
I
p
ar
am
e
te
rs
A
ve
ra
ge
FU
(m
o
)
P
e
rs
o
n
-
ye
ar
s
o
f
FU
O
u
tc
o
m
e
s
FU m
e
th
o
d
Se
q
u
e
n
ce
Fi
e
ld
st
re
n
gt
h
(T
e
sl
a)
E
ch
o
ti
m
e
(m
s)
P
ro
sp
e
ct
iv
e
(1
:2
m
at
ch
e
d
)
(M
IS
T
R
A
L
)
C
o
d
in
g
d
at
a
Q
u
e
st
io
n
n
ai
re
s
to
G
P
s
B
e
n
e
d
ic
tu
s
e
t
al
.4
1
N
e
th
e
rl
an
d
s
(2
0
0
0
–
2
0
1
3
)
P
ro
sp
e
ct
iv
e
(A
m
st
e
rd
am
D
e
m
e
n
ti
a
C
o
h
o
rt
)
3
3
4
(5
3
%
)
(w
it
h
SC
D
)
6
2
3
1
%
8
%
–
–
T
2
*-
G
R
E
1
/1
.5
/3
–
3
6
1
0
0
2
D
e
m
e
n
ti
a
o
r
M
C
I
In
p
e
rs
o
n
(N
e
u
ro
p
sy
ch
-
o
lo
gy
an
d
M
M
SE
)
H
e
n
n
e
m
an
e
t
al
.4
2
N
e
th
e
rl
an
d
s
(1
9
9
3
–
2
0
0
6
)
P
ro
sp
e
ct
iv
e
1
1
3
8
(5
5
%
)
6
6
2
5
%
8
%
–
–
T
2
*-
G
R
E
1
.5
1
5
–
2
2
3
1
2
9
5
9
D
e
at
h
Q
u
e
st
io
n
n
ai
re
s
to
G
P
s
N
o
te
s
St
ae
ke
n
b
o
rg
e
t
al
.4
3
N
e
th
e
rl
an
d
s
P
ro
sp
e
ct
iv
e
1
5
2
(2
7
%
)
(w
it
h
M
C
I)
7
2
–
–
–
–
T
2
*-
G
R
E
1
2
2
2
5
3
3
4
D
e
m
e
n
ti
a
In
p
e
rs
o
n
(N
IN
C
D
S-
A
D
R
D
A
an
d
N
IN
D
S-
A
IR
E
N
)
A
sy
m
p
to
m
a
ti
c
e
ld
e
rl
y
g
e
n
e
ra
l
p
o
p
u
la
ti
o
n
c
o
h
o
rt
s
N
is
h
ik
aw
a
e
t
al
.4
8
Ja
p
an
(2
0
0
3
–
2
0
0
4
)
P
ro
sp
e
ct
iv
e
6
9
8
(4
6
%
)
6
7
4
3
%
1
2
%
1
8
%
T
2
*-
G
R
E
1
.5
2
3
4
2
–
St
ro
ke
In
p
e
rs
o
n
?
A
d
m
is
si
o
n
s/
N
o
te
s
B
o
k
u
ra
e
t
al
.4
9
Ja
p
an
(2
0
0
1
–
2
0
0
7
)
P
ro
sp
e
ct
iv
e
2
2
3
8
6
2
–
–
–
–
T
2
*-
G
R
E
1
.5
2
5
4
3
–
St
ro
ke
P
at
ie
n
t
q
u
e
st
io
n
-
n
ai
re
s
Te
le
p
h
o
n
e
A
ko
u
d
ad
e
t
al
.5
0
N
e
th
e
rl
an
d
s
(2
0
0
5
–
2
0
1
3
)
P
ro
sp
e
ct
iv
e
(R
o
tt
e
rd
am
st
u
d
y)
4
7
5
9
(4
5
%
)
6
4
6
1
%
9
%
2
7
%
T
2
*-
G
R
E
1
.5
3
1
5
9
2
3
3
1
9
St
ro
ke
A
u
to
m
at
e
d
lin
k
ag
e
o
f
G
P
m
e
d
ic
al
re
co
rd
s
an
d
co
d
in
g
d
at
a
A
ko
u
d
ad
e
t
al
.1
2
N
e
th
e
rl
an
d
s
(2
0
0
5
–
2
0
0
9
)
P
ro
sp
e
ct
iv
e
(R
o
tt
e
rd
am
st
u
d
y)
4
8
4
1
(4
5
%
)
6
4
–
–
–
–
T
2
*-
G
R
E
1
.5
3
1
6
2
–
D
e
at
h
G
P
au
to
m
at
ic
u
p
d
at
e
s
C
o
d
in
g
d
at
a
N
o
te
s
A
ko
u
d
ad
e
t
al
.5
1
N
e
th
e
rl
an
d
s
(2
0
0
2
–
2
0
1
4
)
P
ro
sp
e
ct
iv
e
(R
o
tt
e
rd
am
st
u
d
y)
3
2
5
7
(4
5
%
)
(d
e
m
e
n
ti
a-
fr
e
e
)
6
0
–
–
–
–
–
T
2
*-
G
R
E
1
.5
3
1
5
8
–
D
e
m
e
n
ti
a
G
P
au
to
m
at
ic
u
p
d
at
e
s
C
o
d
in
g
d
at
a
In
p
e
rs
o
n
(N
IN
C
D
S-
A
D
R
D
A
,
D
SM
M
D
-3
)
(c
o
n
ti
n
u
e
d
)
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
St
u
d
y
C
o
u
n
tr
y
(s
tu
d
y
p
e
ri
o
d
)
Se
tt
in
g/
co
h
o
rt
d
e
si
gn
C
as
e
s
n
u
m
b
e
r
(%
m
al
e
)
A
ge
(m
e
an
)
H
T
N
(%
)
D
M
(%
)
A
n
ti
p
la
t.
(%
)
A
n
ti
co
ag
s
(%
)
M
R
I
p
ar
am
e
te
rs
A
ve
ra
ge
FU
(m
o
)
P
e
rs
o
n
-
ye
ar
s
o
f
FU
O
u
tc
o
m
e
s
FU m
e
th
o
d
Se
q
u
e
n
ce
Fi
e
ld
st
re
n
gt
h
(T
e
sl
a)
E
ch
o
ti
m
e
(m
s)
R
o
m
e
ro
e
t
al
.5
2
,5
3
,5
7
,5
8
U
SA
P
ro
sp
e
ct
iv
e
(F
ra
m
in
gh
am
h
e
ar
t
st
u
d
y)
1
2
9
6
(4
6
%
)
(d
e
m
e
n
ti
a-
fr
e
e
)
1
9
6
3
(4
6
%
)
7
2
5
0
%
5
6
%
1
3
%
1
4
%
3
0
%
2
9
%
4
%
4
%
T
2
*-
G
R
E
1
.5
2
6
8
0
8
6
8
6
8
7
1
4
1
2
9
D
e
m
e
n
ti
a
St
ro
ke
D
e
at
h
a
In
p
e
rs
o
n
N
o
te
s
A
G
E
S
R
ey
k
ja
vi
k
St
u
d
y5
4
,5
6
Ic
e
la
n
d
(2
0
0
2
–
2
0
1
5
P
ro
sp
e
ct
iv
e
(A
G
E
S
R
ey
k
ja
vi
k
St
u
d
y)
1
9
8
2
(4
2
%
)
4
2
0
6
(4
1
%
)
7
6
8
0
%
1
1
%
2
1
%
7
%
T
2
*-
G
R
E
1
.5
T
5
0
m
s
1
1
1
.6
4
3
9
0
4
3
8
6
2
0
D
e
m
e
n
ti
a
St
ro
ke
D
e
at
h
Ic
e
la
n
d
ic
N
at
io
n
al
R
o
st
e
r
m
ai
n
-
ta
in
e
d
b
y
St
at
is
ti
cs
Ic
e
la
n
d
L
in
k
ag
e
o
f
ad
ju
d
i-
ca
te
d
st
ro
ke
re
gi
st
ri
e
s
an
d
h
o
sp
it
al
m
e
d
-
ic
al
re
co
rd
s
w
it
h
st
u
d
y
d
at
ab
as
e
M
IN
I:
m
in
i
in
te
rn
at
io
n
al
n
e
u
ro
p
sy
ch
ia
tr
ic
in
te
rv
ie
w
;
SC
D
:
su
b
je
ct
iv
e
co
gn
it
iv
e
d
e
cl
in
e
;
M
R
I:
m
ag
n
e
ti
c
re
so
n
an
ce
im
ag
in
g;
T
2
*-
G
R
E
:
T
2
*-
w
e
ig
h
te
d
gr
ad
ie
n
t-
re
ca
lle
d
e
ch
o
;
SW
I:
su
sc
e
p
ti
b
ili
ty
-w
e
ig
h
te
d
im
ag
in
g.
a
Fi
rs
t
ro
w
co
rr
e
sp
o
n
d
s
to
ch
ar
ac
te
ri
st
ic
s
o
f
p
ar
ti
ci
p
an
ts
in
cl
u
d
e
d
in
th
e
d
e
m
e
n
ti
a
o
u
tc
o
m
e
an
al
ys
is
;
se
co
n
d
ro
w
co
rr
e
sp
o
n
d
s
to
th
e
st
ro
ke
/m
o
rt
al
it
y
o
u
tc
o
m
e
s.
N
o
te
:
N
at
io
n
al
In
st
it
u
te
o
n
N
e
u
ro
lo
gi
ca
l
an
d
C
o
m
m
u
n
ic
at
iv
e
D
is
e
as
e
s
an
d
St
ro
ke
-A
lz
h
e
im
e
r
D
is
e
as
e
an
d
R
e
la
te
d
D
is
o
rd
e
rs
A
ss
o
ci
at
io
n
.
V
aD
w
as
d
ia
gn
o
se
d
b
y
N
at
io
n
al
In
st
it
u
te
o
f
N
e
u
ro
lo
gi
ca
l
D
is
o
rd
e
rs
an
d
St
ro
ke
-A
ss
o
ci
at
io
n
In
te
rn
at
io
n
al
e
p
o
u
r
la
R
e
ch
e
rc
h
e´
e
t
l’E
n
se
ig
n
e
m
e
n
t
e
n
N
e
u
ro
sc
ie
n
ce
s
(N
IN
D
S-
A
IR
E
N
).
HR: 2.10; 95% CI: 1.58–2.80, p< 0.0001), with inter-
mediate degree of statistical heterogeneity (Figure 3(b)).
In the meta-analysis of stroke-free individuals from
large population-based studies, CMBs presence was
associated with incident ICH (OR: 7.46; 95% CI:
1.40–39.74, p¼ 0.019) and ischemic stroke risk (OR:
3.59 95% CI: 1.51–8.50, p¼ 0.004), but with high
degree of statistical heterogeneity. Four of these popu-
lation-based cohorts provided adjusted estimates
(n¼ 7695),48–50 while for the ﬁfth one (i.e.
Framingham Heart study),53 the number of incident
stroke events was too low to allow for multivariable
survival analysis. In a subgroup analysis of these stu-
dies, CMBs remained an independent predictor of inci-
dent ICH (adj-HR: 5.50; 95% CI: 3.05–9.92,
p< 0.0001) and, with lower eﬀect size, ischemic stroke
(adj-HR: 1.98; 95% CI: 1.46–2.69, p< 0.0001), again
with high statistical heterogeneity.
The overall meta-analysis combining data from all
populations yielded a signiﬁcant association of CMBs
presence with future ICH and ischemic stroke in both
crude and adjusted analyses, with moderate degree of
statistical heterogeneity (Figures 2 and 3). The relative
risks were overall higher for ICH than ischemic stroke.
CMBs and mortality
Six studies in ischemic stroke/TIA patients
(n¼ 3257),11,21,23,33,37 two memory clinic cohorts
(n¼ 1471),40,42 two studies in high-risk elderly popula-
tions (n¼ 937),44,45 and three population-based studies
(n¼ 8768)12,53,54 investigated the relation between
CMBs and all-cause mortality.
In ischemic stroke/TIA cohorts, CMBs presence
was associated with all-cause mortality both in the
crude analysis (OR: 1.69; 95% CI: 1.17–2.42,
p¼ 0.005) and in adjusted meta-analysis of four studies
(n¼ 2415)11,23,33 providing relevant data (adj-HR: 1.33;
95% CI: 1.03–1.71, p¼ 0.028). A similar eﬀect size was
found in the two studies of memory clinic cohorts in
both unadjusted and adjusted analyses (Figure 4(a) and
(b)). There was no relation between CMBs and
Figure 2. Forest plots of the association between CMBs presence and risk of spontaneous ICH during follow-up. Meta-analysis
performed using a random effects model, with crude odds ratios pooled in (a) and adjusted-hazard ratios pooled in (b). Weights are
shown by the point estimate area.
(a)
(b)
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mortality in high-risk elderly cohorts (Figure 4(a)).
When studies from the four population-based studies
were pooled, CMBs presence was associated with an
increased risk of death during follow-up (OR: 2.45;
95% CI: 1.68–3.57, p< 0.0001, with high statistical het-
erogeneity) and remained an independent predictor
in adjusted meta-analysis (adj-HR: 1.30; 95% CI:
1.17–1.45, p< 0.0001, with no evidence of statistical
heterogeneity) (Figure 4(a) and (b)).
In the overall meta-analysis including all studies
across diﬀerent populations, CMBs presence was an
independent predictor of all-cause mortality during
follow-up (adj-HR: 1.36; 95% CI: 1.24–1.48,
p< 0.0001, with no evidence of statistical heterogen-
eity) (Figure 4(b)).
CMBs and risk of incident dementia
Two memory clinic cohorts (n¼ 486),41,43 two studies in
high-risk elderly populations (n¼ 1024)46,47 and three
population-based studies (n¼ 6535)51,52,54 provided
prospective data on the relation between CMBs
presence and incident dementia overall. The studies
used diﬀerent but validated methods to assign a demen-
tia diagnosis during follow-up (Table 1).
In the two memory clinic studies, CMBs presence was
not associated with dementia during follow-up in the crude
analysis (Figure 4(c)). Of note, these two studies also
included patients with mild cognitive impairment at base-
line and no adjusted estimates could be extracted. In the
two studies in high-risk elderly populations, CMBs pres-
ence at baseline was associated with 2-fold risk of dementia
in the crude meta-analysis (OR: 2.00; 95% CI: 1.22–3.29,
p¼ 0.006), but this eﬀect was not sustained in the adjusted
meta-analysis (adj-HR: 1.04; 95% CI: 0.62–1.76,
p¼ 0.083, with high statistical heterogeneity) (Figure 4(d)).
Meta-analysis of the three population-based studies
(Rotterdam Study,51 Framingham Heart study52 and
AGES Reykjavik Study54), which included dementia-
free participants at baseline, yielded a trend toward
crude association between CMBs presence and incident
dementia, with high degree of statistical heterogeneity
(OR: 2.01; 95% CI: 0.92–4.36, p¼ 0.078) (Figure 4(c)).
However, in adjusted meta-analysis (Figure 4(d)),
Figure 3. Forest plots of the association between CMBs presence and risk of ischemic stroke. Meta-analysis performed using a
random effects model, with crude odds ratios pooled in (a) and adjusted-hazard ratios pooled in (b). Weights are shown by the point
estimate area.
(b)
(a)
International Journal of Stroke, 0(0)
10 International Journal of Stroke 0(0)
CMBs were independently associated with marginally
increased risk of all-cause incident dementia, but with
high statistical heterogeneity (adj-HR: 1.35; 95% CI:
1.00–1.82, p¼ 0.047). Data on dementia subtype were
limited and hence not pooled in a meta-analysis.
Discussion
CMBs are often incidentally detected on MRI in vari-
ous populations and clinical settings raising clinical
dilemmas about the optimal management of patients.4
Figure 4. Forest plots of the association between CMBs presence and mortality (a–b) and dementia (c–d). Meta-analysis were
performed using random effects models, with crude odds ratios for all-cause mortality pooled in (a) and adjusted-hazard ratios
pooled in (b). Crude odds ratios for all-cause dementia were pooled in (c) and adjusted-hazard ratios pooled in (d). Weights are
shown by the point estimate area.
(a)
(b)
(c)
(d)
International Journal of Stroke, 0(0)
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In this systematic review, we brought together data on
clinical relevance of CMBs involving> 22,000 partici-
pants in total. Our meta-analyses provide evidence that
CMBs are an important indicator of future disease,
including ICH, ischemic stroke, death, and dementia,
but with diﬀerent eﬀect sizes, degree of certainty, and
generalizability. The current paper thus provides the
most up-to-date estimates, including-for the ﬁrst time-
adjusted analyses, on the clinical relevance of CMBs
based on the totality of evidence from longitudinal
cohorts. Few evidence-based guidelines exist on how
to best manage patients with incidentally found
CMBs,4 partly due to the paucity of evidence from
large prospective cohorts and the lack of randomized
trials. Accordingly, data from comprehensive meta-
analyses are thus the most informative available
approach for providing actionable information.
CMBs were signiﬁcantly associated with an
increased risk of stroke, both ICH and ischemic
stroke, reinforcing the notion that they are a marker
of subclinical cerebrovascular disease. In patients
with a previous ischemic stroke/TIA, we found that
the presence of CMBs conferred a &4-fold increased
risk of subsequent ICH and &2-fold higher risk of
recurrent ischemic stroke. These results are in line
with previous meta-analyses on the topic,14 but we
have increased our sample size by> 40%, and statis-
tical power by including more outcome events, result-
ing in more precise estimates. It could be argued that
this association between CMBs and future stroke in
confounded by shared vascular risk factors, such as
age and hypertension with both CMBs and future
stroke.1 Indeed, this has been a valid criticism of all
crude, unadjusted meta-analyses on CMBs. In the
adjusted pooled analyses, however, CMBs presence
remained a signiﬁcant predictor of future stroke risk
after taking into account potential confounders,
including vascular risk factors, in studies providing
relevant data. Of note, we observed an approximate
3-fold increase of the independent risk of ICH in the
presence of CMBs and a doubling of the independent
risk for recurrent ischemic stroke. Two points deserve
special notice in these adjusted estimates. First, it
seems that CMBs increase the risk of subsequent
stroke relatively higher towards ICH rather than
ischemic stroke, but more data on absolute risk
ratios are needed. Secondly, the overall independent
risk of ICH conferred by CMBs reported here (when
various other risk factors are accounted for), is in
general lower than previously assumed based on indi-
vidual estimates from small studies or unadjusted
meta-analyses (OR/RR &6–8).4,7,14 It is possible
that the independent ICH risk when> 5 CMBs are
detected might also be lower than reported when vari-
ous confounders are taken into account. This ﬁnding
can have implications for anticoagulation use in
patients with CMBs, a thorny clinical dilemma.
Of note, the abovementioned overall considerations
also apply for stroke-free individuals from large popu-
lation-based studies included in our analysis. We found
that CMBs are also associated with an increased risk of
incident stroke, in particular ICH, in community-dwell-
ing elderly without a prior stroke history. However, the
elevated adjusted-HR for future ICH (&5-fold) in
population-based studies represented a relatively low
absolute event rate: no more than &2–4 incident
ICHs per 1000 person-years among CMB-positive par-
ticipants.50 There was high statistical heterogeneity in
the pooled estimates, likely reﬂecting the low even rate,
diﬀerent baseline characteristics of included popula-
tions, and methodological variation of the studies
(Table 1). These studies found a consistent association
between CMBs and risk of stroke and provide valuable
epidemiological data to strengthen the notion that these
lesions mark progression of silent cerebrovascular path-
ology. Nevertheless, the clinical relevance of CMBs in
healthy elderly populations is uncertain and likely lim-
ited, since routine MRI screening is not generally per-
formed in this setting.
CMBs presence was signiﬁcantly associated with an
increased risk of death during follow-up. This relation-
ship was consistent in all included populations and set-
tings, with similar eﬀect size and no heterogeneity and
maintained in adjusted analyses. The association with
mortality could be plausibly partly mediated by an
increased risk of stroke and dementia in patients with
CMBs11 but this requires further research. The associ-
ation with mortality likely reﬂects CMBs capacity as a
surrogate marker for severe diﬀuse vascular pathology
and frailty, as well as disease-associated vascular risk
factors, rather than a direct causal relationship.1
We found limited data on the relation of CMBs to
new-onset dementia risk during follow-up. Most avail-
able studies to date have been cross-sectional, were car-
ried out in small patient populations and evaluated
cognitive function using diﬀerent instruments.9 A
meta-analysis reported that CMBs were associated
with cognitive dysfunction in two studies (OR: 3.06;
95% CI: 1.59–5.89) and lower cognitive function in
three other studies (standardized mean diﬀerence:
1.06, 95% CI: 2.10 to 0.02) based on the MMSE
or the Montreal cognitive assessment scale (MoCA).9
Another meta-analysis found no signiﬁcant diﬀerence
in the cognitive performance of Alzheimer’s disease
patients with versus without CMBs.60 This is in line
with the absence of any longitudinal relation between
CMBs and incident dementia in memory clinic patients
in our analysis, since presentation to a memory clinic
indicates roughly the same of the mix of neurodegen-
eration and vascular injury, and has similar risk for
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progressing to dementia. The most pertinent and epide-
miologically robust data on CMBs eﬀect on dementia
risk are those from general population samples. In the
three major population-based studies (Rotterdam
Study,51 Framingham Heart study52 and AGES
Reykjavik Study54) pooled in our analysis, CMBs pres-
ence was independently associated with incident
dementia risk, but the association was marginal statis-
tically and with considerable degree of heterogeneity.
However, our analysis primarily focused on the pres-
ence/absence of CMBs. In the recent publication of
AGES Reykjavik study, having 3 CMBs was asso-
ciated with a higher incidence of dementia.56 Whether
the mechanism of the link between CMBs and dementia
is direct and independent of other pathologies in the
ageing brain, or simply reﬂect more severe small
vessel damage, remains speculative.51 Most likely,
CMBs represent a surrogate of diﬀuse cerebral micro-
vascular damage, and hence their presence inﬂuences
dementia risk only indirectly.51
Several limitations of our study are important to
consider. First, our crude meta-analyses used unad-
justed OR which are prone to bias introduced by the
diﬀerent populations and methodology (including MRI
parameters for CMBs detection) in included studies.
For example, imaging protocols and CMBs analysis
were similar but not entirely uniform; most studies
were performed at 1.5 T with echo times within a
narrow optimal range, making this factor unlikely to
inﬂuence our conclusions. To account for various con-
founding eﬀects, we also present pooled adjusted esti-
mates. However, covariate-adjusted HR was not
available in all studies resulting in residual confound-
ing. The largest studies with adequate outcome events
were more likely to present multivariable analyses. Of
note, in all adjusted analyses, the sample size
was> 1500 subjects, which is the pre-speciﬁed sample
of large ongoing studies in the ﬁeld.61 Second, given the
variability in follow-up time between studies, calcula-
tion of absolute outcome event rates was not possible.
We acknowledge that there is likely substantial hetero-
geneity among the various subjects classiﬁed as CMBs
positive, including diﬀerent CMBs burden and distribu-
tion per subject. In turn, the CMBs distribution reﬂects
diﬀerent types of cerebral small vessel diseases with
intrinsically distinct risk for the outcomes we studied.
Cerebral amyloid angiopathy is typically associated
with multiple CMBs in strictly lobar brain regions,
whereas non-amyloid-related microangiopathies
(including the vascular risk factor driven process of
arteriolosclerosis) commonly lead to CMBs in deep dis-
tribution.62 Finally, given the strong association of vas-
cular risk factors, other small vessel disease MRI
markers and antithrombotic drugs during follow-up
both with CMBs and with the clinical outcomes we
studied, it would be important to dissect the modifying
eﬀect of these risk factors on the reported associations.
Despite limitations, our comprehensive meta-analy-
sis signiﬁcantly illuminates the understanding of the
clinical relevance of CMBs in terms of future stroke,
death, and dementia risk. It generally supports that the
discovery of CMBs should prompt detailed screening
for risk factors of stroke and dementia and recommen-
dations regarding aggressive measures of prevention.
The pooled estimates presented, based on large
sample sizes, can inform clinical decision-making guide-
lines on increasingly common dilemmas posed by
CMBs, clinical trials in the ﬁeld and patient counseling.
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